SCHEMBL3000559

SCHEMBL3000559

CCc1ccc(-c2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.59
MAPK1 P28482 4/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
ALDH1A1 P00352 3/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
MAPT P10636 7/20 0.56
USP2 O75604 1/20 0.51
RECQL P46063 1/20 0.51
HSD17B10 Q99714 1/20 0.51
AR P10275 3/20 0.49
HTT P42858 1/20 0.48
PKM P14618 2/20 0.47
PKLR P30613 1/20 0.47
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011269 0.92 LMNA (0.57) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018469 0.90 SMN1; SMN2 (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3014464 0.89 SMN1; SMN2 (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008963 0.87 LMNA (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3005812 0.87 LMNA (0.67) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3013174 0.86 SMN1; SMN2 (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018745 0.86 PKM (0.47) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008789 0.86 MAPT (0.63) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3012140 0.85 ALDH1A1 (0.64) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3004195 0.84 SMN1; SMN2 (0.83) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.